A PHASE I, OPEN-LABEL, MULTICENTER, 3-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ACENOCOUMAROL IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY

Trial Profile

A PHASE I, OPEN-LABEL, MULTICENTER, 3-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ACENOCOUMAROL IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Vemurafenib (Primary) ; Acenocoumarol
  • Indications Malignant melanoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 04 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Oct 2013 Planned end date changed from 1 May 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 07 Oct 2013 Planned end date changed from 1 Jul 2014 to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top